Shilpa Medicare · NSE: SHILPAMED · BSE: 530549

Q4 FY25 results · Jan–Mar 2025

Shilpa Medicare reported revenue from operations of ₹330.80 crore (up 13.4% from Q4 FY24) and net profit of ₹14.51 crore (down 40.8% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.

Consolidated · ₹ crore
ItemQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue from operations330.80291.69+13.4%319.32+3.6%
Other income7.572.49+203.7%1.13+568.9%
Total income338.38294.19+15.0%320.45+5.6%
Profit before share of associates & JVs and tax12.9827.85−53.4%41.27−68.6%
Share of profit/(loss) of associates & JVs2.30(0.14)0.34
Net profit for the period14.5124.50−40.8%31.78−54.4%
EPS, basic (₹)1.482.82not comparable3.25−54.5%
Net margin (%)4.48.410.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue from operations126.1587.45+44.3%125.39+0.6%
Other income14.0823.25−39.4%16.83−16.3%
Total income140.24110.70+26.7%142.21−1.4%
Profit before tax(9.43)11.43Turned loss25.33Turned loss
Net profit for the period(5.15)9.74Turned loss16.12Turned loss
EPS, basic (₹)(0.53)1.12not comparable1.65Turned loss
Net margin (%)-4.111.112.9
Consolidated
Filed with BSE
06 Nov 2025, 16:52 IST
Board meeting
26 May 2025
Period
01 Jan 2025 to 31 Mar 2025
Review status
Audited
Source
XBRL filing on BSE
Standalone
Filed with BSE
06 Nov 2025, 16:52 IST
Board meeting
26 May 2025
Period
01 Jan 2025 to 31 Mar 2025
Review status
Audited
Source
XBRL filing on BSE